Company
Headquarters: Shantou, China
Employees: 842
CEO: Mr. Chuanglong Yao
HK$928.8 Million
HKD as of July 1, 2024
US$118.9 Million
| Company | Market Cap (USD) |
|---|---|
| McKesson Corporation | $75.67 B |
| Cencora, Inc. | $43.82 B |
| Cardinal Health, Inc. | $23.31 B |
| Shanghai Pharmaceuticals Holding Co. Ltd | $8.79 B |
| Sinopharm Group Co. Ltd | $8.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, and healthcare products to downstream distributors and terminal chemists, as well as related consulting services. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Charmacy Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: HKEX: 2289 wb_incandescent